Please assess the completion status of the following clinical trial:

Trial Title: ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Repeated, spontaneous epistaxis in a known Rendu Osler patient who wants global caring, these must be daily epistaxis (\> 28 a month) or a total amount of 60 minutes of bleeding a month (50 % Rendu-Osler patients bleed before 20 and 99 % at 50 when penetrance is complete).~* Good completion of the grid of control by recording the number and duration of epistaxis over a period of three month.~Exclusion Criteria:~* Rendu Osler syndrome with specific phenotype : absence of epistaxis or occasional epistaxis, no need for particular care.~* Maintained expectations of an ENT treatment of epistaxis in a delay of three months.~* Incapacity of detailing the number of epistaxis, especially, at least, within three months before entering the study.~* No informed consent obtained after informing the patient on his participation to the study.~* Expected lack of observance because of an incapacity to compel to the daily treatment.~* Formal indication to Tranexamic Acid (angioneurotic oedema as a disease modifying treatment of 3 to 4 g/ day).~* Contra-indications to Tranexamic acid: history of convulsion, arterial or veinous thrombosis, , positivity of veinous echo doppler of the inferior limbs; Serum creatinine \> 250 µmol/l.~N.B. Cases of bad observance are not frequent, patients being highly concerned with a treatment to reduce their discomfort and anaemia. They are more likely ready to move to a centre insuring this handling. Nevertheless, lack of observance will be detected over a period of 15 days of placebo in simple blind, before randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).